Hsbc Holdings PLC Acquires New Stake in COMPASS Pathways PLC Sponsored ADR $CMPS

Hsbc Holdings PLC bought a new position in COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 1,075,485 shares of the company’s stock, valued at approximately $3,011,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vivo Capital LLC boosted its position in shares of COMPASS Pathways by 109.1% during the 1st quarter. Vivo Capital LLC now owns 3,362,385 shares of the company’s stock valued at $9,616,000 after acquiring an additional 1,754,385 shares during the last quarter. Nantahala Capital Management LLC lifted its position in COMPASS Pathways by 182.9% during the first quarter. Nantahala Capital Management LLC now owns 2,829,232 shares of the company’s stock valued at $8,092,000 after purchasing an additional 1,829,232 shares during the last quarter. GMT Capital Corp grew its stake in COMPASS Pathways by 15.1% in the 1st quarter. GMT Capital Corp now owns 1,781,718 shares of the company’s stock worth $5,096,000 after buying an additional 233,918 shares in the last quarter. Woodline Partners LP increased its holdings in shares of COMPASS Pathways by 279.9% in the 1st quarter. Woodline Partners LP now owns 1,754,856 shares of the company’s stock worth $5,019,000 after buying an additional 1,292,927 shares during the last quarter. Finally, Aisling Capital Management LP increased its holdings in shares of COMPASS Pathways by 24.3% in the 1st quarter. Aisling Capital Management LP now owns 1,198,418 shares of the company’s stock worth $3,427,000 after buying an additional 233,918 shares during the last quarter. Hedge funds and other institutional investors own 46.19% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on CMPS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of COMPASS Pathways in a report on Wednesday, October 8th. BTIG Research raised their price target on COMPASS Pathways from $7.00 to $14.00 and gave the company a “buy” rating in a research report on Monday, October 13th. Finally, Morgan Stanley upped their price objective on COMPASS Pathways from $10.00 to $11.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $15.88.

COMPASS Pathways Price Performance

CMPS stock opened at $5.82 on Friday. The firm has a market cap of $558.84 million, a P/E ratio of -2.14 and a beta of 1.93. The firm’s fifty day moving average is $5.90 and its 200 day moving average is $4.88. COMPASS Pathways PLC Sponsored ADR has a 52 week low of $2.25 and a 52 week high of $7.09. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.23 and a current ratio of 1.23.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.02. Research analysts predict that COMPASS Pathways PLC Sponsored ADR will post -2.33 earnings per share for the current year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.